JP2024525740A5 - - Google Patents

Info

Publication number
JP2024525740A5
JP2024525740A5 JP2024501799A JP2024501799A JP2024525740A5 JP 2024525740 A5 JP2024525740 A5 JP 2024525740A5 JP 2024501799 A JP2024501799 A JP 2024501799A JP 2024501799 A JP2024501799 A JP 2024501799A JP 2024525740 A5 JP2024525740 A5 JP 2024525740A5
Authority
JP
Japan
Prior art keywords
cancer
pharmaceutically acceptable
compound according
stereoisomer
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024501799A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024525740A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/073782 external-priority patent/WO2023288305A1/en
Publication of JP2024525740A publication Critical patent/JP2024525740A/ja
Publication of JP2024525740A5 publication Critical patent/JP2024525740A5/ja
Pending legal-status Critical Current

Links

JP2024501799A 2021-07-16 2022-07-15 小分子サイクリン依存性キナーゼ4/6(cdk4/6)およびikzf2(helios)分解剤並びにその使用方法 Pending JP2024525740A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163222646P 2021-07-16 2021-07-16
US63/222,646 2021-07-16
PCT/US2022/073782 WO2023288305A1 (en) 2021-07-16 2022-07-15 Small molecule cyclin dependent kinase 4/6 (cdk4/6) and ikzf2 (helios) degraders and methods of use thereof

Publications (2)

Publication Number Publication Date
JP2024525740A JP2024525740A (ja) 2024-07-12
JP2024525740A5 true JP2024525740A5 (cg-RX-API-DMAC7.html) 2025-07-23

Family

ID=84919760

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024501799A Pending JP2024525740A (ja) 2021-07-16 2022-07-15 小分子サイクリン依存性キナーゼ4/6(cdk4/6)およびikzf2(helios)分解剤並びにその使用方法

Country Status (7)

Country Link
US (1) US20240376096A1 (cg-RX-API-DMAC7.html)
EP (1) EP4370126A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024525740A (cg-RX-API-DMAC7.html)
CN (1) CN117396208A (cg-RX-API-DMAC7.html)
AU (1) AU2022311961A1 (cg-RX-API-DMAC7.html)
CA (1) CA3217661A1 (cg-RX-API-DMAC7.html)
WO (1) WO2023288305A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3217792A1 (en) 2021-05-07 2022-11-10 Kymera Therapeutics, Inc Cdk2 degraders and uses thereof
CN118488948A (zh) 2021-12-22 2024-08-13 吉利德科学公司 Ikaros锌指家族降解剂及其用途
PL4245756T3 (pl) 2022-03-17 2025-02-17 Gilead Sciences, Inc. Środki degradujące palec cynkowy z rodziny ikaros i ich zastosowania
CN118420612A (zh) * 2023-02-01 2024-08-02 沈阳药科大学 一种基于cdk4/6抑制剂的靶向蛋白降解化合物及制备方法和用途
WO2025245178A1 (en) * 2024-05-21 2025-11-27 Innovo Therapeutics, Inc. Pak4, cstf2, or cstf2t protein degraders, pharmaceutical compositions, and therapeutic applications

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ534069A (en) 2002-01-22 2007-03-30 Warner Lambert Co 2-(Pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones to be used to treat neurodegenerative disorders, viruses and cancer
US7968569B2 (en) 2002-05-17 2011-06-28 Celgene Corporation Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
TWI398252B (zh) 2006-05-26 2013-06-11 諾華公司 吡咯并嘧啶化合物及其用途
WO2009014642A1 (en) * 2007-07-19 2009-01-29 Amgen Inc. Combination of a de novo purine biosynthesis inhibitor and a cyclin dependent kinase inhibitor for the treatment of cancer
AU2009284098B2 (en) 2008-08-22 2012-03-29 Astex Therapeutics Ltd. Pyrrolopyrimidine compounds as CDK inhibitors
TW201014830A (en) 2008-09-30 2010-04-16 Theravance Inc Crystalline form of an alkoxyimidazol-1-ylmethyl biphenyl carboxylic acid
AR083797A1 (es) 2010-11-10 2013-03-20 Novartis Ag Succinato de dimetil-amida del acido 7-ciclopentil-2-(5-piperazin-1-il-piridin-2-il-amino)-7h-pirrolo-[2,3-d]pirimidin-6-carboxilico, proceso para prepararla, intermediarios de dicha sintesis y proceso de preparacion de los mismos
US9345705B2 (en) 2011-09-15 2016-05-24 Merck Sharp & Dohme Corp. Compositions and methods for treating cancer
DK3431475T3 (da) 2013-02-21 2021-05-25 Pfizer Faste former af en selektiv CDK4/6-hæmmer
SI4197530T1 (sl) 2015-04-16 2026-03-31 Novartis Ag Tableta ribocikliba
AU2017254702B2 (en) * 2016-04-22 2020-12-24 Dana-Farber Cancer Institute, Inc. Degradation of cyclin-dependent kinase 9 (CDK9) by conjugation of CDK9 inhibitors with E3 ligase ligand and methods of use
SG11202003415XA (en) * 2017-10-18 2020-05-28 Novartis Ag Compositions and methods for selective protein degradation
EP3778590A4 (en) * 2018-04-09 2021-12-22 ShanghaiTech University ANTI PROTEIN DEGRADATION COMPOUND, ANTITUMOR APPLICATION, INTERMEDIATE THEREOF, AND INTERMEDIATE USE
CA3123519A1 (en) * 2019-02-15 2020-08-20 Novartis Ag Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof

Similar Documents

Publication Publication Date Title
RU2468021C2 (ru) Гетероциклические соединения и их применение
JP2020508302A5 (cg-RX-API-DMAC7.html)
JP2022071077A5 (cg-RX-API-DMAC7.html)
JP2020517616A5 (cg-RX-API-DMAC7.html)
CA2922575C (en) Pharmaceutical combinations for the treatment of cancer
EA016577B1 (ru) Конъюгаты антитело-лекарство и их применение
JP2015512943A5 (cg-RX-API-DMAC7.html)
JP2015512398A5 (cg-RX-API-DMAC7.html)
JP2008528671A5 (cg-RX-API-DMAC7.html)
US10759803B2 (en) Asparagine endopeptidase (AEP) inhibitors for managing cancer and compositions related thereto
US9801898B2 (en) Glutamate dehydrogenase 1 inhibitors and methods of treating cancer
US20160113925A1 (en) Methods of treating cancer with a combination of glucose modulators and bcl-2 inhibitors
KR20160110952A (ko) 암을 치료하기 위한 신규한 방법
JP2012526766A5 (cg-RX-API-DMAC7.html)
JP2021530444A5 (cg-RX-API-DMAC7.html)
KR20070010125A (ko) 인테그린과 선택적으로 결합하는 피페리디닐 표적화 화합물
JP2024515809A5 (cg-RX-API-DMAC7.html)
JP2024125139A5 (cg-RX-API-DMAC7.html)
JP2009503110A5 (cg-RX-API-DMAC7.html)
US9266901B2 (en) Compositions and methods for treating cancer
JP2012522842A5 (cg-RX-API-DMAC7.html)
JP2022539840A5 (cg-RX-API-DMAC7.html)
JP2009510165A5 (cg-RX-API-DMAC7.html)
CN105283456A (zh) 5-溴-靛玉红
JP6450678B2 (ja) 新規な化合物およびその使用